Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.

Essen Health Care announced that it is participating in the Guiding an Improved Dementia Experience (GUIDE) Model, an ...

Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

CStone, the drug’s developer, previously announced similar deals with various pharmaceutical companies to expand sugemalimab ...

Health In Tech announced new partnerships that it says will allow it to introduce a new self-funded health plan. 1 The ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.